A multicenter, multinational, placebo controlled, randomized phase II/III clinical trial of cannabidiol for the treatment of acute graft-versus-host-disease (GVHD)

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 14 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Jun 2018 According to a Kalytera Therapeutics media release, this trial will initiate later in 2018.
21 Jun 2018 According to a Kalytera Therapeutics media release, the Principal Investigator of this study is Edmund Waller, M.D., PhD., Professor, Hematology and Medical Oncology, Medicine, and Pathology at Emory University School of Medicine, and Director, Division of Stem Cell Transplantation and Immunotherapy at Winship Cancer Institute of Emory University.
15 Jun 2018 According to a Kalytera Therapeutics media release, The Salzman Group will provide clinical study management services for this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com